GI Innovation Inc
KOSDAQ:358570
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Mogu Inc
NYSE:MOGU
|
CN |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
|
CN |
GI Innovation Inc
Long-Term Debt
GI Innovation Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GI Innovation Inc
KOSDAQ:358570
|
Long-Term Debt
₩11.1B
|
CAGR 3-Years
45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Long-Term Debt
₩412.3B
|
CAGR 3-Years
39%
|
CAGR 5-Years
15%
|
CAGR 10-Years
4%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Long-Term Debt
₩466.2B
|
CAGR 3-Years
198%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Long-Term Debt
₩409.7m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Long-Term Debt
₩4.2B
|
CAGR 3-Years
75%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Long-Term Debt
₩189.1m
|
CAGR 3-Years
-83%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
GI Innovation Inc
Glance View
GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
See Also
What is GI Innovation Inc's Long-Term Debt?
Long-Term Debt
11.1B
KRW
Based on the financial report for Dec 31, 2024, GI Innovation Inc's Long-Term Debt amounts to 11.1B KRW.
What is GI Innovation Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
45%
Over the last year, the Long-Term Debt growth was 282%. The average annual Long-Term Debt growth rates for GI Innovation Inc have been 45% over the past three years .
